Pharma BD Deal Intelligence
Daiichi Sankyo hands China commercialization of an approved FLT3 inhibitor to Innovent
Full analysis, sources & comparables →Innovent Biologics and Daiichi Sankyo entered an exclusive agreement for commercialization of VANFLYTA (quizartinib) in China. Innovent holds sole commercialization rights in China and leads market promotion, while Daiichi Sankyo remains responsible for development, manufacturing and supply. VANFLYTA is a FLT3 inhibitor approved in Japan, the United States and Europe for relapsed or refractory FLT3-ITD positive acute myeloid leukemia, and was approved in China in June 2026 in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for newly diagnosed FLT3-ITD positive AML. VANFLYTA becomes the 20th product in Innovent's commercialized portfolio. Financial terms were not disclosed.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Innovent Biologics, Inc. / Daiichi Sankyo Company, Limited (this deal) | 2026 | — | 64 |
| Servier Pharmaceuticals LLC / Day One Biopharmaceuticals Inc. | 2026 | $2.5B | 75 |
| Servier / Edgewise Therapeutics, Inc. | 2026 | $2.6B | 75 |
| AstraZeneca PLC / Dizal Pharmaceutical Co., Ltd | 2026 | $1.5B | 73 |
| Travere Therapeutics, Inc. / Everest Medicines Limited | 2026 | $1.1B | 72 |
| AbbVie Inc. / Apogee Therapeutics, Inc. | 2026 | $10.9B | 72 |
| Pfizer Inc. / Innovent Biologics, Inc. | 2026 | $10.5B | 71 |
← Browse all deals · How we score deals
More: 2026 deals